Entries by

Making mAb Accessible webinar

The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI are pleased to invite you to join a webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention:

“Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’

HVTN 084 – Injectable HIV drug prevents infections

The IAS hosted Global HIV Vaccine Enterprise welcomes interim results showing effectiveness of long-acting injectable PrEP. New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill in a trial of women at increased risk of HIV acquisition.

VIRTUAL WORKSHOP SERIES

NOW VIRTUAL ! This scientific and technical workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID. Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs.

HIV Vaccine Roadmap at AIDS 2020 Virtual!

With over 600 virtual sessions and events, AIDS 2020: Virtual will enable delegates to access and engage with the latest HIV science, advocacy and knowledge traditionally presented at the conference, while offering a range of new features made possible by the new virtual format. Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Download the HIV vaccine, and vaccine research roadmap.

What years of HIV vaccine research can teach us about the search for a COVID-19 vaccine

SARS-CoV-2, the virus that causes COVID-19, has taken the world by surprise, just as HIV did in the 1980’s. However, unlike HIV, the world has come together and shown that a coordinated, global response to a pandemic is possible in record time. Many aspects of this response, including the search for a vaccine, have built upon technologies and lessons learned from recent epidemics, including HIV.

HVTN 702 Uhambo

Every year, World Immunization Week is celebrated during the last week of April with the aim of promoting the use of vaccines to protect people against infectious diseases. Although much progress has been made to develop vaccines, an HIV vaccine remains elusive. In this post we revisit one of the most promising HIV prevention vaccine studies that was prematurely halted due to lack of efficacy and highlight its critical role in informing HIV vaccine development.

“Bench to Clinic” web tool relaunched

The Enterprise is relaunching the “Bench to Clinic” web tool in the context of ongoing efficacy trials, a rich pipeline of new products and new approaches to the design and development of HIV vaccines. The tools provides an overview of the necessary steps in the process and estimates of corresponding timelines and budgets. It also drew attention to some potential challenges and provided links to relevant resources.

Enterprise workshop trial design R4P

This scientific and technical workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID. Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs.

HIV R4P 2020 Abstract submissions now open

The Global HIV Vaccine Enterprise encourages HIV vaccine researches to submit abstracts online from 3 February to 23 April through the HIVR4P website. Late breaker abstracts will be accepted from 23 July – 5 August. Abstracts about HIV vaccine research and development can be submitted across a range of categories from basic science to product implementation.